{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:54:56Z","timestamp":1794048896537,"version":"4.8.0"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"21","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lymphangioleiomyomatosis (LAM), a rare multisystem disease found primarily in women of childbearing age, is characterized by the proliferation of abnormal smooth muscle\u2013like cells, LAM cells, that form nodules in the pulmonary interstitium. Proliferation of LAM cells results, in part, from dysfunction in tuberous sclerosis complex (TSC) genes TSC1 (hamartin) and\/or TSC2 (tuberin). Identification of LAM cells in donor lungs, their isolation from blood, and their presence in urine, chylous ascites, and pleural effusions are consistent with their ability to metastasize. Here, we investigated the presence on LAM cells of the hyaluronic acid receptor CD44 and its splice variants associated with metastasis. The heterogeneous populations of cells grown from lungs of 12 LAM patients contain cells expressing mRNA for the variant CD44v6. Histologically, CD44v6 was present in LAM lung nodules, but not in normal vascular smooth muscle cells. CD44v6-positive sorted cells showed loss of heterozygosity at the TSC2 locus; binding of CD44v6 antibody resulted in loss of cell viability. Levels of CD44 were higher in cultured Eker rat (Tsc2\u2212\/\u2212) cells than in Tsc2+\/+ cells, but unlike human LAM cells, the Tsc2\u2212\/\u2212 Eker rat cells did not contain CD44v6 splice variant mRNA. CD44 splicing and signaling is regulated by osteopontin. Plasma from LAM patients contained higher concentrations of osteopontin than plasma of healthy, age-, and sex-matched volunteers (P = 0.00003) and may be a biomarker for LAM. The cell surface receptor CD44 and its splice variant CD44v6 may contribute to the metastatic potential of LAM cells. [Cancer Res 2007;67(21):10573\u201381]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-1356","type":"journal-article","created":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T17:58:14Z","timestamp":1193939894000},"page":"10573-10581","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["<i>TSC2<\/i> Loss in Lymphangioleiomyomatosis Cells Correlated with Expression of CD44v6, a Molecular Determinant of Metastasis"],"prefix":"10.1158","volume":"67","author":[{"given":"Gustavo","family":"Pacheco-Rodriguez","sequence":"first","affiliation":[{"name":"1Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy K.","family":"Steagall","sequence":"additional","affiliation":[{"name":"1Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Crooks","sequence":"additional","affiliation":[{"name":"1Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"Stevens","sequence":"additional","affiliation":[{"name":"1Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"1Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-an","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Darling","sequence":"additional","affiliation":[{"name":"2Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Moss","sequence":"additional","affiliation":[{"name":"1Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,11,1]]},"reference":[{"key":"2022061623214190700_B1","doi-asserted-by":"crossref","unstructured":"Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med\u20082006; 173: 105\u201311.","DOI":"10.1164\/rccm.200409-1298OC"},{"key":"2022061623214190700_B2","doi-asserted-by":"crossref","unstructured":"Pacheco-Rodriguez G, Kristof AS, Stevens LA, et al. Giles F. Filley Lecture. Genetics and gene expression in lymphangioleiomyomatosis. Chest\u20082002; 121: 56\u201360S.","DOI":"10.1378\/chest.121.3_suppl.56S"},{"key":"2022061623214190700_B3","doi-asserted-by":"crossref","unstructured":"Jo\u0301z\u0301wiak S, Schwartz RA, Janniger CK, Michalowicz R, Chmielik J. Skin lessions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Derm\u20081998; 37: 911\u20137.","DOI":"10.1046\/j.1365-4362.1998.00495.x"},{"key":"2022061623214190700_B4","doi-asserted-by":"crossref","unstructured":"Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A\u20082000; 97: 6085\u201390.","DOI":"10.1073\/pnas.97.11.6085"},{"key":"2022061623214190700_B5","doi-asserted-by":"crossref","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell\u20082006; 124: 471\u201384.","DOI":"10.1016\/j.cell.2006.01.016"},{"key":"2022061623214190700_B6","doi-asserted-by":"crossref","unstructured":"Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem\u20082002; 277: 30958\u201367.","DOI":"10.1074\/jbc.M202678200"},{"key":"2022061623214190700_B7","doi-asserted-by":"crossref","unstructured":"Ferrans VJ, Yu ZX, Nelson WK, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch\u20082000; 67: 311\u201329.","DOI":"10.1272\/jnms.67.311"},{"key":"2022061623214190700_B8","doi-asserted-by":"crossref","unstructured":"Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A\u20082004; 101: 17462\u20137.","DOI":"10.1073\/pnas.0407971101"},{"key":"2022061623214190700_B9","doi-asserted-by":"crossref","unstructured":"Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer\u20082003; 38: 376\u201381.","DOI":"10.1002\/gcc.10252"},{"key":"2022061623214190700_B10","doi-asserted-by":"crossref","unstructured":"Karbowniczek M, Yu J, Henske EP. Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol\u20082003; 162: 491\u2013500.","DOI":"10.1016\/S0002-9440(10)63843-6"},{"key":"2022061623214190700_B11","doi-asserted-by":"crossref","unstructured":"Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol\u20082003; 34: 95\u20138.","DOI":"10.1053\/hupa.2003.50"},{"key":"2022061623214190700_B12","doi-asserted-by":"crossref","unstructured":"Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol\u20082003; 4: 33\u201345.","DOI":"10.1038\/nrm1004"},{"key":"2022061623214190700_B13","doi-asserted-by":"crossref","unstructured":"Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol\u20082004; 35: 211\u201331.","DOI":"10.1023\/B:HIJO.0000032354.94213.69"},{"key":"2022061623214190700_B14","doi-asserted-by":"crossref","unstructured":"Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell\u20081991; 65: 13\u201324.","DOI":"10.1016\/0092-8674(91)90403-L"},{"key":"2022061623214190700_B15","doi-asserted-by":"crossref","unstructured":"Weg-Remers S, Ponta H, Herrlich P, Konig H. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J\u20082001; 20: 4194\u2013203.","DOI":"10.1093\/emboj\/20.15.4194"},{"key":"2022061623214190700_B16","doi-asserted-by":"crossref","unstructured":"Bajorath J. Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. Proteins\u20082000; 39: 103\u201311.","DOI":"10.1002\/(SICI)1097-0134(20000501)39:2<103::AID-PROT1>3.0.CO;2-G"},{"key":"2022061623214190700_B17","doi-asserted-by":"crossref","unstructured":"Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ\u20082006; 13: 465\u201377.","DOI":"10.1038\/sj.cdd.4401763"},{"key":"2022061623214190700_B18","doi-asserted-by":"crossref","unstructured":"Okamoto I, Kawano Y, Murakami D, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol\u20082001; 155: 755\u201362.","DOI":"10.1083\/jcb.200108159"},{"key":"2022061623214190700_B19","unstructured":"Recio JA, Merlino G. Hepatocyte growth factor\/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res\u20082003; 63: 1576\u201382."},{"key":"2022061623214190700_B20","doi-asserted-by":"crossref","unstructured":"Gao C, Guo H, Downey L, et al. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis\u20082003; 24: 1871\u20138.","DOI":"10.1093\/carcin\/bgg139"},{"key":"2022061623214190700_B21","doi-asserted-by":"crossref","unstructured":"Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell\u20081994; 5: 565\u201374.","DOI":"10.1091\/mbc.5.5.565"},{"key":"2022061623214190700_B22","doi-asserted-by":"crossref","unstructured":"Agnihotri R, Crawford HC, Haro H, et al. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem\u20082001; 276: 28261\u20137.","DOI":"10.1074\/jbc.M103608200"},{"key":"2022061623214190700_B23","unstructured":"Katagiri YU, Sleeman J, Fujii H, et al. CD44 variants but not CD44s cooperate with \u03b21-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res\u20081999; 59: 219\u201326."},{"key":"2022061623214190700_B24","doi-asserted-by":"crossref","unstructured":"Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol\u20082006; 16: 79\u201387.","DOI":"10.1016\/j.tcb.2005.12.005"},{"key":"2022061623214190700_B25","doi-asserted-by":"crossref","unstructured":"Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell\u20082005; 7: 121\u20137.","DOI":"10.1016\/j.ccr.2005.01.017"},{"key":"2022061623214190700_B26","doi-asserted-by":"crossref","unstructured":"Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer\u20082002; 2: 563\u201372.","DOI":"10.1038\/nrc865"},{"key":"2022061623214190700_B27","doi-asserted-by":"crossref","unstructured":"Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother\u20082004; 53: 567\u201379.","DOI":"10.1007\/s00262-003-0494-4"},{"key":"2022061623214190700_B28","doi-asserted-by":"crossref","unstructured":"Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science\u20081999; 284: 143\u20137.","DOI":"10.1126\/science.284.5411.143"},{"key":"2022061623214190700_B29","doi-asserted-by":"crossref","unstructured":"Hudson DL, Sleeman J, Watt FM. CD44 is the major peanut lectin-binding glycoprotein of human epidermal keratinocytes and plays a role in intercellular adhesion. J Cell Sci\u20081995; 108: 1959\u201370.","DOI":"10.1242\/jcs.108.5.1959"},{"key":"2022061623214190700_B30","doi-asserted-by":"crossref","unstructured":"Kasper M, Gunthert U, Dall P, et al. Distinct expression patterns of CD44 isoforms during human lung development and in pulmonary fibrosis. Am J Respir Cell Mol Biol\u20081995; 13: 648\u201356.","DOI":"10.1165\/ajrcmb.13.6.7576702"},{"key":"2022061623214190700_B31","doi-asserted-by":"crossref","unstructured":"Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol\u20082002; 15: 434\u201340.","DOI":"10.1038\/modpathol.3880543"},{"key":"2022061623214190700_B32","doi-asserted-by":"crossref","unstructured":"Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, et al. Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell\u20082001; 7: 823\u201332.","DOI":"10.1016\/S1097-2765(01)00226-X"},{"key":"2022061623214190700_B33","doi-asserted-by":"crossref","unstructured":"Schmid I, Uittenbogaart CH, Keld B, Giorgi JV. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J Immunol Methods\u20081994; 170: 145\u201357.","DOI":"10.1016\/0022-1759(94)90390-5"},{"key":"2022061623214190700_B34","doi-asserted-by":"crossref","unstructured":"Soucek T, Yeung RS, Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci U S A\u20081998; 95: 15653\u20138.","DOI":"10.1073\/pnas.95.26.15653"},{"key":"2022061623214190700_B35","doi-asserted-by":"crossref","unstructured":"Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci\u20082004; 95: 930\u20135.","DOI":"10.1111\/j.1349-7006.2004.tb03179.x"},{"key":"2022061623214190700_B36","doi-asserted-by":"crossref","unstructured":"Matsui K, Takeda K, Yu ZX, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med\u20082000; 124: 267\u201375.","DOI":"10.5858\/2000-124-0267-RFAOMM"},{"key":"2022061623214190700_B37","doi-asserted-by":"crossref","unstructured":"Zhe X, Yang Y, Jakkaraju S, Schuger L. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol\u20082003; 28: 504\u201311.","DOI":"10.1165\/rcmb.2002-0124OC"},{"key":"2022061623214190700_B38","doi-asserted-by":"crossref","unstructured":"Zhe X, Yang Y, Schuger L. Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor. Am J Respir Cell Mol Biol\u20082005; 32: 28\u201334.","DOI":"10.1165\/rcmb.2004-0289OC"},{"key":"2022061623214190700_B39","doi-asserted-by":"crossref","unstructured":"Ferri N, Carragher NO, Raines EW. Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis. Am J Pathol\u20082004; 164: 1575\u201385.","DOI":"10.1016\/S0002-9440(10)63716-9"},{"key":"2022061623214190700_B40","doi-asserted-by":"crossref","unstructured":"Lammich S, Okochi M, Takeda M, et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an A\u03b2-like peptide. J Biol Chem\u20082002; 277: 44754\u20139.","DOI":"10.1074\/jbc.M206872200"},{"key":"2022061623214190700_B41","doi-asserted-by":"crossref","unstructured":"Murakami D, Okamoto I, Nagano O, et al. Presenilin-dependent \u03b3-secretase activity mediates the intramembranous cleavage of CD44. Oncogene\u20082003; 22: 1511\u20136.","DOI":"10.1038\/sj.onc.1206298"},{"key":"2022061623214190700_B42","doi-asserted-by":"crossref","unstructured":"Hebbard L, Steffen A, Zawadzki V, et al. CD44 expression and regulation during mammary gland development and function. J Cell Sci\u20082000; 113: 2619\u201330.","DOI":"10.1242\/jcs.113.14.2619"},{"key":"2022061623214190700_B43","doi-asserted-by":"crossref","unstructured":"Zhu B, Suzuki K, Goldberg HA, et al. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J Cell Physiol\u20082004; 198: 155\u201367.","DOI":"10.1002\/jcp.10394"},{"key":"2022061623214190700_B44","doi-asserted-by":"crossref","unstructured":"Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med\u20082005; 11: 284\u201392.","DOI":"10.1016\/j.molmed.2005.04.005"},{"key":"2022061623214190700_B45","doi-asserted-by":"crossref","unstructured":"Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF\/c-Met signaling. Genes Dev\u20082002; 16: 3074\u201386.","DOI":"10.1101\/gad.242602"},{"key":"2022061623214190700_B46","doi-asserted-by":"crossref","unstructured":"Lamb RF, Roy C, Diefenbach TJ, et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol\u20082000; 2: 281\u20137.","DOI":"10.1038\/35010550"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/21\/10573\/2574900\/10573.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/21\/10573\/2574900\/10573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:55:58Z","timestamp":1655434558000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/21\/10573\/533661\/TSC2-Loss-in-Lymphangioleiomyomatosis-Cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,1]]},"references-count":46,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2007,11,1]]},"published-print":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-1356","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,1]]}}}